Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2005, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company historically operated as a drug discovery firm but has been unsuccessful in advancing research programs. Management is currently focused on redeploying residual assets and studying strategic direction. As of May 11, 2005, there were 16,266,618 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Expenses | $331,000 | $769,000 |
| Operating Loss | $(331,000) | $(769,000) |
| Net Loss | $(290,000) | $(739,000) |
| Net Loss Attributable to Common Shareholders | $(524,000) | $(962,000) |
| Loss Per Share (Basic & Diluted) | $(0.03) | $(0.06) |
| Cash and Cash Equivalents (End of Period) | $8,409,000 | $9,405,000 |
| Restricted Cash | $175,000 | $175,000 |
| Marketable Securities | $1,038,000 | $1,124,000 |
| Total Assets | $9,644,000 | $10,071,000 |
| Total Liabilities | $192,000 | $239,000 |
| Net Cash Used in Operating Activities | $(325,000) | $(811,000) |
Material Changes vs. Prior Period
- Expense Reduction: General and administrative expenses decreased by $438,000 (57%) compared to the prior year quarter. This reduction was driven by lower officer salaries ($128,000), reduced director and officer insurance premiums ($133,000), and decreased legal and accounting fees ($86,000).
- Net Loss Improvement: Net loss attributable to common shareholders improved significantly from $(962,000) in Q1 2004 to $(524,000) in Q1 2005, primarily due to the reduction in operating expenses.
- Interest Income: Other income increased to $41,000 from $30,000, attributed to higher interest rates.
- Liquidity: Cash and cash equivalents decreased by $325,000 during the quarter, reflecting the net cash used in operations. There were no proceeds from financing activities in Q1 2005, compared to $84,000 from option exercises in Q1 2004.
Outlook, Risks, and Contingencies
- Strategic Direction: The Board has established a committee to study strategic direction and identify potential business opportunities, as the company has been unsuccessful in advancing its historical drug discovery programs.
- Legal Proceedings:
- Weiss Litigation: A class action lawsuit filed in 2003 against former directors was dismissed with prejudice by the Delaware Court of Chancery on April 12, 2005.
- Labidi Proceeding: A former employee filed a lawsuit alleging discrimination, harassment, and wrongful conversion of research materials. Mediation occurred in May 2005 with no settlement reached. Discovery is ongoing, and a trial is set for November 2005.
- Accounting Changes: The company expects to adopt SFAS No. 123R (Share-Based Payment) effective January 1, 2006. The financial impact beyond 2005 has not yet been determined.
- Investment Risk: Marketable securities consist of equity in Intrac, Inc., which are not fully tradable pending registration. These investments carry risks of loss and price volatility.
Key Facts for Investor Verification
- Verify the company's current strategic pivot, as it has ceased active drug discovery and is redeploying assets.
- Monitor the status of the Labidi Proceeding, with a trial scheduled for November 2005, as a potential liability.
- Confirm the liquidity runway given the continued net cash burn of approximately $325,000 per quarter with no revenue.
- Check the tradability status of the $1.038 million investment in Intrac, Inc. stock, which is currently restricted.
- Review the impact of the upcoming SFAS 123R adoption on future stock-based compensation expenses.